EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparing the Clinical Performance of Paclitaxel‐Coated Balloons and Paclitaxel‐Eluting Stent for Treating Long Femoropopliteal Artery Disease: Results of the CAPELLA Study

Naoki Yoshioka iD, Takahiro Tokuda iD, Akiko Tanaka iD, Shunsuke Kojima iD, Kohei Yamaguchi, Takashi Yanagiuchi iD, Kenji Ogata iD, Tatsuro Takei iD, Yasuhiro Morita, Tatsuya Nakama iD, Itsuro Morishima iD, LEADers PAD investigators

Catheterization and Cardiovascular Interventions · 2026

DOI: 10.1002/ccd.70387 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Naoki Yoshioka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan. Hauptthemen laut MEDLINE: Paclitaxel, Popliteal Artery, Femoral Artery, Peripheral Arterial Disease. Die Arbeit nennt 43 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies reported comparable outcomes between paclitaxel‐coated balloons (PCBs) and paclitaxel‐eluting stents (PESs) for femoropopliteal artery disease. However, data comparing the clinical performance of these paclitaxel devices for longer lesions in real‐world clinical settings remains limited.

Methods

In this multicenter, retrospective study, the clinical performance of the PCBs (IN.PACT and Ranger) without bailout stenting and PESs (Eluvia) were assessed in cases of femoropopliteal artery disease with lesion length ≥ 150 mm. From the database, 376 lesions in 376 individuals were assigned to the PCB group, and 268 lesions in 268 individuals were assigned to the PES group. Propensity score‐matching analysis was performed to adjust for baseline individual and lesion characteristics. The primary outcome was 2‐year primary patency (PP), mainly determined using duplex ultrasound, and the secondary outcomes were clinically driven target lesion revascularization, acute limb ischemia, major amputation, and mortality.

Results

Propensity score matching identified 134 pairs with no significant intergroup differences in baseline individual and lesion characteristics. Average lesion length was 252.0 and 253.2 mm in the PCB and PES groups, respectively. Within 2 years, the PES group demonstrated significantly higher PP than the PCB group (80.1% vs. 68.4%, p = 0.037). In contrast, the secondary outcomes did not significantly differ between the groups. No baseline characteristics showed a significant interaction effect on the association of PCBs vs PES with loss of PP.

Conclusion

PP was significantly higher in the PES group than the PCB group in real‐world populations with longer, complex lesions, whereas other outcomes did not significantly differ between the two groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelPopliteal ArteryFemoral ArteryPeripheral Arterial DiseaseCardiovascular AgentsDrug-Eluting StentsCoated Materials, BiocompatibleAngioplasty, BalloonVascular Access DevicesHumansRetrospective StudiesMaleFemaleAgedTreatment OutcomeVascular PatencyTime FactorsMiddle AgedRisk FactorsProsthesis DesignLimb SalvageAmputation, SurgicalDatabases, FactualAged, 80 and over

Stichwörter der Autor:innen

endovascular therapylong lesionlower extremity peripheral artery diseasepaclitaxel‐coated balloonspaclitaxel‐eluting stentpropensity score matching

Substanzen

PaclitaxelCardiovascular AgentsCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.
  • Department of Cardiology, Sendai Kousei Hospital, Sendai, Japan.
  • Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan.
  • Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan.
  • Department of Cardiology, Rakuwakai Otowa Hospital, Kyoto, Japan.

ORCID-Profile: Naoki Yoshioka, Takahiro Tokuda, Akiko Tanaka, Shunsuke Kojima, Takashi Yanagiuchi, Kenji Ogata, Tatsuro Takei, Tatsuya Nakama, Itsuro Morishima

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Yoshioka, N., Tokuda, T., Tanaka, A., Kojima, S., Yamaguchi, K., Yanagiuchi, T., Ogata, K., Takei, T., Morita, Y., Nakama, T., Morishima, I., & LEADers PAD investigators (2026). Comparing the Clinical Performance of Paclitaxel‐Coated Balloons and Paclitaxel‐Eluting Stent for Treating Long Femoropopliteal Artery Disease: Results of the CAPELLA Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70387

Vancouver

Yoshioka N, Tokuda T, Tanaka A, Kojima S, Yamaguchi K, Yanagiuchi T, et al. Comparing the Clinical Performance of Paclitaxel‐Coated Balloons and Paclitaxel‐Eluting Stent for Treating Long Femoropopliteal Artery Disease: Results of the CAPELLA Study. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70387

BibTeX
@article{Yoshioka2026,
  author = {Yoshioka, Naoki and Tokuda, Takahiro and Tanaka, Akiko and Kojima, Shunsuke and Yamaguchi, Kohei and Yanagiuchi, Takashi and Ogata, Kenji and Takei, Tatsuro and Morita, Yasuhiro and Nakama, Tatsuya and Morishima, Itsuro and LEADers PAD investigators, LEADers PAD investigators},
  title = {Comparing the Clinical Performance of Paclitaxel‐Coated Balloons and Paclitaxel‐Eluting Stent for Treating Long Femoropopliteal Artery Disease: Results of the CAPELLA Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70387}
}
Kostenlos starten →